OPK

Business Context and Reporting Period

This Form 10-Q covers the quarterly period ended March 31, 2002, for Exegenics Inc. (Note: The input metadata references "OPKO HEALTH, INC.", but the filing text explicitly identifies the issuer as Exegenics Inc.). The company is a post-genomics drug creation enterprise focused on developing therapeutic products for cancer and drug-resistant bacterial diseases. During the quarter, the company restructured its internal scientific projects to focus on proprietary technologies (QCT and OASIS) following the conclusion of a major research funding agreement.

Key Financial Metrics

Material Changes vs. Prior Period

• Revenue Stability: Revenue remained flat at $333,000, entirely derived from licensing and research fees from Bristol-Myers Squibb (BMS). However, management notes that the final BMS payment was received in February 2002, and BMS will not provide additional funding, effectively ending the company's sole revenue source.
• Increased Losses: Net loss attributable to common shareholders increased by $418,000 (27.5%) to $1.938 million. This was driven by higher operating expenses and a significant drop in interest income.
• Expense Growth:
  • Research and Development (R&D) expenses rose 5% to $1.241 million due to increased consultant fees and facility costs.
  • General and Administrative (G&A) expenses rose 13% to $1.061 million, primarily due to higher legal fees for intellectual property and business development consulting.
• Interest Income Decline: Interest income dropped from $461,000 in Q1 2001 to $189,000 in Q1 2002, attributed to lower interest rates and reduced principal balances.
• Cash Burn: Net cash used in operating activities increased significantly from $459,000 to $1.345 million.

Outlook, Risks, and Management Commentary

• Strategic Pivot: The company is shifting focus to leveraging proprietary technologies to create novel compounds and is exploring acquisition/merger opportunities for clinical-stage drug candidates.
• Restructuring: The company eliminated several scientific and administrative positions. Estimated severance payments of $50,000 are expected to be recognized in Q2 2002. Previous restructuring costs of approximately $560,000 were recognized through March 31, 2002.
• Liquidity: As of March 31, 2002, the company held approximately $24.3 million in cash, cash equivalents, and investments. Management believes this is sufficient to fund operations through December 31, 2002.
• Risks:
  • Revenue Risk: The company has lost its sole source of revenue (BMS funding) and cannot assure when, or if, significant revenue will be generated again.
  • Financing Risk: There is no assurance that future financing (debt or equity) will be available on acceptable terms after the current cash runway expires.
  • Development Risk: No assurance exists that the company will successfully discover commercially viable drug leads or secure partners for its programs.
• Unusual Items: The company recorded stock-based compensation charges of $85,100 for the quarter ($39,100 for new grants and $46,000 for prior grants).

Investor Verification Checklist

• Verify the company's ability to generate new revenue streams immediately following the termination of the Bristol-Myers Squibb funding.
• Confirm the timeline and success of the planned acquisition or merger activities for clinical-stage drug candidates.
• Monitor cash burn rates to ensure the $24.3 million liquidity position remains sufficient to reach the projected December 2002 runway.
• Assess the progress of the new anti-bacterial agents and tuberculosis enzyme target research announced in April 2002.
• Review the status of potential partnerships for the glucocerebrosidase production system intended for Gaucher's Disease treatment.